Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

Tirapazamine (TPZ) is a new anticancer drug that is activated specifically at the low oxygen level typically found in solid tumours. It exhibits preferential cytotoxicity towards hypoxic cells and has been shown in preclinical studies with transplanted tumours and in phase II and III clinical trials to potentiate the anti-tumour efficacy of cisplatin without increasing its systemic toxicity. At present, the mechanism for this potentiation is unknown. Here we show that there is a schedule-dependent enhancement of cisplatin cytotoxicity by TPZ for cells in vitro that is similar to that seen with transplanted murine tumours. This cisplatin potentiation depends on the TPZ exposure being at oxygen concentrations below 1%, which are typical of many cells in tumours but not in normal tissues. Also, the interaction between TPZ and cisplatin does not occur in cells mutant in ERCC4, a protein essential for repair of DNA interstrand cross-links. Incubation of the cells with TPZ under hypoxia prior to cisplatin treatment increases cisplatin-induced DNA interstrand cross-links with kinetics suggesting that TPZ inhibits or delays repair of the DNA cross-links. In conclusion, we show that the tumour-specific potentiation of cisplatin cytotoxicity is likely the result of an interaction between TPZ and cisplatin at the cellular level that requires the low oxygen levels typical of those in solid tumours. The mechanism of the interaction appears to be through a potentiation of cisplatin-induced DNA interstrand cross-links, possibly as a result of a diminished or delayed repair of these lesion

In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells

<p>Abstract</p> <p>Background</p> <p>Based on their different mechanisms of action, non-overlapping side effects and radiosensitising potential, combining the antimetabolites pemetrexed (multitargeted antifolate, MTA) and gemcitabine (2',2'-difluorodeoxycytidine, dFdC) with irradiation (RT) seems promising. This <it>in vitro </it>study, for the first time, presents the triple combination of MTA, dFdC and irradiation using various treatment schedules.</p> <p>Methods</p> <p>The cytotoxicity, radiosensitising potential and cell cycle effect of MTA were investigated in A549 (NSCLC) and CAL-27 (SCCHN) cells. Using simultaneous or sequential exposure schedules, the cytotoxicity and radiosensitising effect of 24 h MTA combined with 1 h or 24 h dFdC were analysed.</p> <p>Results</p> <p>Including a time interval between MTA exposure and irradiation seemed favourable to MTA immediately preceding or following radiotherapy. MTA induced a significant S phase accumulation that persisted for more than 8 h after drug removal. Among different MTA/dFdC combinations tested, the highest synergistic interaction was produced by 24 h MTA followed by 1 h dFdC. Combined with irradiation, this schedule showed a clear radiosensitising effect.</p> <p>Conclusions</p> <p>Results from our <it>in vitro </it>model suggest that the sequence 24 h MTA → 1 h dFdC → RT is the most rational design and would, after confirmation in an <it>in vivo </it>setting, possibly provide the greatest benefit in the clinic.</p

Triazine-mediated controlled radical polymerization: New unimolecular initiators

Triazine-based unimolecular initiators are shown to mediate the controlled radical polymerization of several monomer classes, yielding polymers with low dispersities, targeted molecular weights, and active chain ends. We report the modular synthesis of structurally and electronically diverse triazine-based unimolecular initiators and demonstrate their ability to efficiently control the radical polymerization of modified styrene monomers. Copolymerizations of styrene with butyl acrylate or methyl methacrylate were conducted to highlight the monomer family tolerance of this system. Notably, in the case of methyl methacrylate and styrene, up to 90 mol% methyl methacrylate comonomer loadings could be achieved while maintaining a controlled polymerization, allowing the synthesis of a range of block copolymers. This class of triazine-based mediators has the potential to complement current methods of controlled radical polymerization and marks an important milestone in ongoing efforts to develop initiators and mediators with high monomer tolerance that are both metal and sulfur-free

Highly efficient organic photocatalysts discovered via a computer-aided-design strategy for visible-light-driven atom transfer radical polymerization

Organocatalysed photoredox-mediated atom transfer radical polymerization (O-ATRP) is a very promising polymerization method as it eliminates concerns associated with transition-metal contamination of polymer products. However, reducing the amount of catalyst and expanding the monomer scope remain major challenges in O-ATRP. Herein, we report a systematic computer-aided-design strategy to identify powerful visible-light photoredox catalysts for O-ATRP. One of our discovered organic photoredox catalysts controls the polymerization of methyl methacrylate at sub-ppm catalyst loadings (0.5 ppm-a very meaningful amount enabling the direct use of polymers without a catalyst removal process); that is, 100-1,000 times lower loadings than other organic photoredox catalysts reported so far. Another organic photoredox catalyst with supra-reducing power in an excited state and high redox stability facilitates the challenging polymerization of the non-acrylic monomer styrene, which is not successful using existing photoredox catalysts. This work provides access to diverse challenging organic/polymer syntheses and makes O-ATRP viable for many industrial and biomedical applications